| Primary | Blood Alcohol Concentration | Blood alcohol concentration (BAC) level was determined 6 times over 6 hours to assess for changes in BAC from use of an e-cigarette containing ethanol compared to the use of an e-cigarette without ethanol. | Blood Alcohol Concentration (% alcohol) | Posted | | Mean | Standard Deviation | percent alcohol | | Blood collected before (baseline) and after (0, 40, 55, 200, 215) drinking. The e-cigarette was used at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
| | | Title | Denominators | Categories |
|---|
| Baseline Collection | | | Title | Measurements |
|---|
| - OG0000± 0
- OG0010± 0
- OG0020± 0
- OG003
|
|
| |
| Primary | Breath Alcohol Concentration | Breath Alcohol Concentration (BrAC) was assessed 12 times over 6 hours to determine changes in BrAC from the use of an e-cigarette containing ethanol compared to the use of an e-cigarette without ethanol. | Blood Alcohol Concentration (% alcohol) | Posted | | Mean | Standard Deviation | percent alcohol | | Breath was analyzed before (baseline) and after (10, 20, 40, 55, 90, 120, 165, 200, 215, 240, 270 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Oral Fluid Alcohol Concentration (OFAC) | Oral fluid alcohol concentration (OFAC) was assessed 9 times over 6 hours to determine changes in OFAC from the use of an e-cigarette containing ethanol compared to use of an e-cigarette without ethanol. | Blood Alcohol Concentration (% alcohol) | Posted | | Mean | Standard Deviation | Percent Alcohol | | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarker (5-Hydroxytryptophol) in Blood | 5-Hydroxytryptophol was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarker (5-Hydroxytryptophol) ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Blood | 5-Hydroxyindoleacetic acid was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Blood/ E-cig Containing Ethanol | Ethyl sulfate was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Ethyl Sulfate) ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood | Phosphatidylethanol 16:0-18:1 was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Blood ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood | Phosphatidylethanol 16:0-18:2 was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Blood ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood was collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) Analyzed in Blood | 5-Hydroxytryptophol glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) in Blood ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (5-Hydroxytryptophol) in Blood | Ethyl glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Ethyl Glucuronide ) in Blood ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (5-Hydroxytryptophol) in Analyzed in Oral Fluid | 5-Hydroxyindoleacetic acid was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (5-Hydroxytryptophol) in Oral Fluid ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | |
|
| Primary | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) Analyzed in Oral Fluid | 5-Hydroxyindoleacetic acid was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (5-Hydroxyindoleacetic Acid) in Oral Fluid ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | |
|
| Primary | Ethanol Biomarkers (Ethyl Sulfate) Analyzed in Oral Fluid | Ethyl sulfate was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Ethyl Sulfate) in Oral Fluid ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Primary | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) Analyzed in Blood | Phosphatidylethanol 16:0-18:1 was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:1) in Oral Fluid ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | |
|
| Primary | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid | Phosphatidylethanol 16:0-18:2 was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Phosphatidylethanol 16:0-18:2) in Oral Fluid ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participants at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | |
|
| Primary | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Blood | Ethyl glucuronide was analyzed in blood 6 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (5-Hydroxytryptophol Glucuronide) ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Blood collected before (baseline) and after (0, 40, 55, 200, 215 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking. | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | On four separate occasions, participants will come to the research center and complete one of the four conditions. All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes. Beverage with ethanol and E-cigarette liquid with ethanol: Beverage with ethanol and E-cigarette liquid with ethanol Beverage with ethanol and E-cigarette liquid without ethanol: Beverage with ethanol and E-cigarette liquid without ethanol Beverage without ethanol and E-cigarette liquid with ethanol: Beverage without ethanol and E-cigarette liquid with ethanol Beverage without ethanol and E-cigarette liquid without ethanol: Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | On four separate occasions, participants will come to the research center and complete one of the four conditions. All participants will complete all four study conditions. Sessions will be ordered by Latin-square. Participants will not be assigned to arms based on session order and session order will not be recorded as it is not relevant to the study outcomes. |
|
| Primary | Ethanol Biomarkers (Ethyl Glucuronide) Analyzed in Oral Fluid | Ethyl glucuronide was analyzed in oral fluid 9 times over a course of 6 hours to assess changes in determined concentrations from use of an electronic cigarette containing ethanol. | Ethanol Biomarkers (Ethyl Glucuronide) in Oral Fluid ng/mL | Posted | | Mean | Standard Deviation | ng/mL | | Oral fluid was collected before (baseline) and after (0, 5, 20, 40, 55, 200, 215, 240 min) drinking. The e-cigarette was used by the participant at 50 and 210 minutes post-drinking | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | | OG003 | Active Drink: Active Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid with 20% ethanol |
|
| Secondary | Horizontal Gaze Nystagmus | Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the Horizontal Gaze Nystagmus (a jerking or stuttering type of movement observed in a person's eyes that occurs as a result of consuming alcohol or other nervous system depressants) test. For each test, a law enforcement officer records the number of clues observed. HGN has a maximum of 6 clues, 3 per eye:
- lack of smooth pursuit
- distinct and sustained nystagmus at maximum deviation
- onset of nystagmus prior to 45 degrees.
| Horizontal Gaze Nystagmus # of clues observed | Posted | | Mean | Standard Deviation | Number of Clues Observed | | Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol |
|
| Secondary | Walk and Turn Test | Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the walk and turn test (suspect to perform a physical task while simultaneously following instructions and maintaining balance; involves walking a straight line heel-to-toe, turning, and walking back, with officers looking for specific indicators of impairment). For each test, a law enforcement officer records the number of clues observed. WAT has a maximum of 8 clues:
- inability to balance during the instruction phase
- starting before the officer has finished the instructions
- Stopping while walking to regain balance
- Not touching heel-to-toe
- Stepping off the line
- Using arms to balance
- Losing balance on the turn or turning incorrectly
- Taking the wrong number of steps
| Walk and Turn Test, # of clues observed | Posted | | Mean | Standard Deviation | Number of Clues Observed | | Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol |
|
| Secondary | One Leg Stand Test | Standard Field Sobriety Tests (SFSTs) were administered 4 times over a course of 6 hours to assess changes in objective impairment. The SFST includes the one-leg stand test (assess balance and coordination, potentially indicating impairment due to alcohol or drugs). For each test, a law enforcement officer records the number of clues observed. OLS has a maximum of 4 clues: Swaying while balancing, Using arms for balance, Hopping 4. Putting the raised foot down | One leg stand test, # of clues observed | Posted | | Mean | Standard Deviation | Number of Clues observed | | Conducted before drinking (baseline), at 20 minutes post-drinking (before first vaping bout), at 55 minutes post-drinking (after the first vaping), and at 215 minutes post-drinking (after second vaping bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol |
|
| Other Pre-specified | Subjective High Assessment Scale Questionnaire (SHAS) | Subjective High Assessment Scale Questionnaire (SHAS) is a 14-item questionnaire used to assess how intoxicated a person feels after consuming alcohol, typically administered in laboratory settings. It focuses on capturing subjective sensations associated with intoxication, such as feeling "clumsy," "dizzy," or "high". Participants rate their experience on a visual analog scale (a line with markings) to indicate the extent to which they feel each symptom at a given time. The scale ranges from Normal" (0) to "Extremely" (100). The score for each of the questions is summed to give an overall indication of the individual's subjective intoxication. A higher score would indicate greater feelings of impairment. | Subjective High Assessment Scale Questionnaire (SHAS) Total score | Posted | | Mean | Standard Deviation | SHAS Total score | | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape |
|
| Other Pre-specified | Biphasic Alcohol Effects Scale Questionnaire (BAES) | Biphasic Alcohol Effects Scale Questionnaire (BAES) is a 14-item questionnaire consisting of adjectives that describe the stimulant- and sedative-like effects of alcohol. The items are presented in alphabetical order, and are rated on an 11-point rating scale from 0=Not at All to 10=Extremely. The score for each of the questions was summed to give an overall indication of the individual's subjective intoxication. A higher score would indicate greater feelings of impairment. | Biphasic Alcohol Effects Scale Questionnaire (BAES) total score | Posted | | Mean | Standard Deviation | (BAES) total score | | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol |
|
| Other Pre-specified | General Labeled Magnitude Scale Questionnaire (gLMS) | The general labeled magnitude scale (gLMS) is a psychophysical scaling method used to measure the perceived intensity of various sensations. A gLMS typically ranges from 0 (undetectable) to 100 (strongest imaginable sensation/experience of any kind). Crucially, it uses specific labels positioned at specific points on the scale (e.g., barely detectable, weak, moderate, strong, very strong). The gLMS was comprised of 3 questions asking participants to indicate the overall flavor sensation, harshness, and throat hit of the e-cigarette. The score for each of the questions was summed. A higher score would indicate greater sensations from e-cigarette use. | General Labeled Magnitude Scale Questionnaire (gLMS) total score | Posted | | Mean | Standard Deviation | (gLMS) total score | | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | |
|
| Other Pre-specified | Labeled Hedonic Scale Questionnaire (LHS) | A survey tool used to measure how much someone likes or dislikes something using descriptive labels for different levels of liking and disliking. Instead of just numbers, the scale uses words or phrases that describe the intensity of liking or disliking (e.g., "most disliked sensation imaginable"=0, "neutral" = 50, and "most liked sensation imaginable"=100) and aim to provide ratio-level data, meaning that the differences between scale points are meaningful and proportional. the LHS was comprised of 4 questions asking participants to indicate the e-cigarette's overall flavor sensation, harshness, throat hit, and warmth of the vapor. The score for each of the questions was summed. A higher score would indicate a more liked overall vaping experience; a lower score would indicate a more disliked overall vaping experience | Labeled Hedonic Scale Questionnaire (LHS) total score | Posted | | Mean | Standard Deviation | (LHS) total score | | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 |
|
| Other Pre-specified | Direct Effects of Vaping Questionnaire (DEPVQ) | Direct Effects of Vaping Questionnaire (DEVQ) is a 10-item Questionnaire that asks participants about their vaping experience (10 questions, each scored from 0 - 100). While subscale scores are often the primary focus, an overall score may be calculated by summing all item scores or averaging them. The score for each of the questions was summed. A higher score indicates the e-cigarette evoked greater subjective effects or feelings. | Direct Effects of Vaping Questionnaire (DEPVQ) total score | Posted | | Mean | Standard Deviation | (DEPVQ) total score | | Administered at baseline, 55 minutes post-drinking (after first vape bout), and 215 minutes post-drinking (after second vape bout). | | | | ID | Title | Description |
|---|
| OG000 | Placebo Drink: Placebo Vape | Beverage without ethanol and E-cigarette liquid without ethanol | | OG001 | Placebo Drink: Active Vape | Beverage without ethanol and E-cigarette liquid with 20% ethanol | | OG002 | Active Drink: Placebo Vape | Beverage with 50% ethanol (dosed to have the participant reach a 0.08% BAC) and E-cigarette liquid without ethanol | |
|